Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 14.4% in October

Entera Bio Ltd. (NASDAQ:ENTX) saw a large drop in short interest in October. As of October 15th, there was short interest totalling 40,400 shares, a drop of 14.4% from the September 30th total of 47,200 shares. Based on an average daily volume of 37,300 shares, the short-interest ratio is currently 1.1 days.

Institutional Trading of Entera Bio

An institutional investor recently bought a new position in Entera Bio stock. Virtu Financial LLC acquired a new position in shares of Entera Bio Ltd. (NASDAQ:ENTX) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 22,040 shares of the company’s stock, valued at approximately $37,000. 14.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Entera Bio in a research report on Monday, October 7th.

Entera Bio Stock Performance

Shares of ENTX stock traded down $0.05 during trading hours on Thursday, reaching $1.81. The company had a trading volume of 10,630 shares, compared to its average volume of 119,944. Entera Bio has a 12-month low of $0.52 and a 12-month high of $3.35. The company has a market capitalization of $64.77 million, a price-to-earnings ratio of -6.56 and a beta of 1.57. The stock has a fifty day moving average of $1.86 and a 200-day moving average of $1.95.

Entera Bio (NASDAQ:ENTX) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06). The firm had revenue of $0.06 million during the quarter. On average, analysts forecast that Entera Bio will post -0.23 EPS for the current year.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.